Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 50,477 shares of the stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $17.81, for a total transaction of $898,995.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kurt Von Emster also recently made the following trade(s):

  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.51, for a total transaction of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.63, for a total transaction of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.60, for a total transaction of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.84, for a total transaction of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.56, for a total transaction of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.26, for a total transaction of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.90, for a total transaction of $730,113.80.
  • On Tuesday, June 27th, Kurt Von Emster sold 81,435 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.08, for a total transaction of $1,390,909.80.
  • On Friday, June 23rd, Kurt Von Emster sold 32,368 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.23, for a total transaction of $525,332.64.

Crispr Theraptc (NASDAQ:CRSP) traded up 0.54% during trading on Monday, reaching $18.50. 177,286 shares of the company’s stock were exchanged. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The stock has a 50-day moving average of $16.34 and a 200-day moving average of $17.57. The stock’s market capitalization is $739.94 million.

Crispr Theraptc (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.06. The business had revenue of $2.70 million during the quarter. On average, equities research analysts anticipate that Crispr Theraptc will post ($2.46) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Crispr Theraptc (NASDAQ:CRSP) Director Sells 50,477 Shares of Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/07/insider-selling-crispr-theraptc-nasdaqcrsp-director-sells-50477-shares-of-stock.html.

CRSP has been the subject of several research analyst reports. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective for the company. Finally, Cann initiated coverage on shares of Crispr Theraptc in a research report on Monday, July 17th. They issued a “market perform” rating for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $21.92.

Institutional investors have recently made changes to their positions in the stock. IHT Wealth Management LLC acquired a new position in shares of Crispr Theraptc during the first quarter worth about $110,000. Monashee Investment Management LLC increased its stake in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. Paulson & CO. Inc. purchased a new stake in Crispr Theraptc during the first quarter valued at $1,099,000. Wellington Management Group LLP increased its stake in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Finally, Credit Suisse AG purchased a new stake in Crispr Theraptc during the first quarter valued at $1,742,000. 24.08% of the stock is owned by hedge funds and other institutional investors.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.